Since its development in 1911, allergen-specific immunotherapy (AIT) still remains the only standard of care for the treatment of IgE-mediated allergic diseases, such as allergic rhinitis (AR), bronchial asthma (BA), and hymenopterum venom anaphylaxis (HVA). This evidence concerns the gene IGHE and allergic disease.